In light of their already beneficial utility in the management of diabetes, the use of NLY01 and other GLP-1R agonists is particularly promising in their potential for the treatment of PDR, the leading cause of blindness in working-age adults in developed countries worldwide. This evidence concerns the gene GLP1R and diabetes mellitus.